Cargando…
A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice
Atherosclerosis is a chronic inflammatory disease of the arterial walls that develops at predisposed sites. As a major risk factor for adverse cardiovascular pathology, atherosclerosis can progress to myocardial infarction and stroke, due to the rupture of unstable atherosclerotic lesions. Macrophag...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270736/ https://www.ncbi.nlm.nih.gov/pubmed/37332345 http://dx.doi.org/10.3389/fphar.2023.1204905 |
_version_ | 1785059377932140544 |
---|---|
author | Gauvin, Jade Frégeau, Geneviève Elimam, Hanan Ménard, Liliane Huynh, David Lê, Catherine Ahsanullah, Ahsanullah Lubell, William D. Ong, Huy Marleau, Sylvie |
author_facet | Gauvin, Jade Frégeau, Geneviève Elimam, Hanan Ménard, Liliane Huynh, David Lê, Catherine Ahsanullah, Ahsanullah Lubell, William D. Ong, Huy Marleau, Sylvie |
author_sort | Gauvin, Jade |
collection | PubMed |
description | Atherosclerosis is a chronic inflammatory disease of the arterial walls that develops at predisposed sites. As a major risk factor for adverse cardiovascular pathology, atherosclerosis can progress to myocardial infarction and stroke, due to the rupture of unstable atherosclerotic lesions. Macrophage uptake of modified lipoproteins and metabolic dysfunction contributes significantly to the initiation and development of atherosclerotic lesions. The cluster of differentiation 36 receptor [CD36 (SR-B2)] plays a key role in atherosclerotic lesion progression and acts as an efferocytic molecule in the resolution of advanced plaque. In previous studies, linear azapeptide CD36 ligands were shown to exhibit anti-atherosclerotic properties. In the present study, a novel potent and selective macrocyclic azapeptide CD36 ligand, MPE-298, has proven effective in protecting against atherosclerosis progression. Features of greater plaque stability were observed after 8 weeks of daily injections with the cyclic azapeptide in apolipoprotein E-deficient mice fed a high-fat high-cholesterol diet. |
format | Online Article Text |
id | pubmed-10270736 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102707362023-06-16 A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice Gauvin, Jade Frégeau, Geneviève Elimam, Hanan Ménard, Liliane Huynh, David Lê, Catherine Ahsanullah, Ahsanullah Lubell, William D. Ong, Huy Marleau, Sylvie Front Pharmacol Pharmacology Atherosclerosis is a chronic inflammatory disease of the arterial walls that develops at predisposed sites. As a major risk factor for adverse cardiovascular pathology, atherosclerosis can progress to myocardial infarction and stroke, due to the rupture of unstable atherosclerotic lesions. Macrophage uptake of modified lipoproteins and metabolic dysfunction contributes significantly to the initiation and development of atherosclerotic lesions. The cluster of differentiation 36 receptor [CD36 (SR-B2)] plays a key role in atherosclerotic lesion progression and acts as an efferocytic molecule in the resolution of advanced plaque. In previous studies, linear azapeptide CD36 ligands were shown to exhibit anti-atherosclerotic properties. In the present study, a novel potent and selective macrocyclic azapeptide CD36 ligand, MPE-298, has proven effective in protecting against atherosclerosis progression. Features of greater plaque stability were observed after 8 weeks of daily injections with the cyclic azapeptide in apolipoprotein E-deficient mice fed a high-fat high-cholesterol diet. Frontiers Media S.A. 2023-05-30 /pmc/articles/PMC10270736/ /pubmed/37332345 http://dx.doi.org/10.3389/fphar.2023.1204905 Text en Copyright © 2023 Gauvin, Frégeau, Elimam, Ménard, Huynh, Lê, Ahsanullah, Lubell, Ong and Marleau. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Gauvin, Jade Frégeau, Geneviève Elimam, Hanan Ménard, Liliane Huynh, David Lê, Catherine Ahsanullah, Ahsanullah Lubell, William D. Ong, Huy Marleau, Sylvie A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice |
title | A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice |
title_full | A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice |
title_fullStr | A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice |
title_full_unstemmed | A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice |
title_short | A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice |
title_sort | cyclic azapeptide ligand of the scavenger receptor cd36/sr-b2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein e-deficient mice |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270736/ https://www.ncbi.nlm.nih.gov/pubmed/37332345 http://dx.doi.org/10.3389/fphar.2023.1204905 |
work_keys_str_mv | AT gauvinjade acyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice AT fregeaugenevieve acyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice AT elimamhanan acyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice AT menardliliane acyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice AT huynhdavid acyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice AT lecatherine acyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice AT ahsanullahahsanullah acyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice AT lubellwilliamd acyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice AT onghuy acyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice AT marleausylvie acyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice AT gauvinjade cyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice AT fregeaugenevieve cyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice AT elimamhanan cyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice AT menardliliane cyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice AT huynhdavid cyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice AT lecatherine cyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice AT ahsanullahahsanullah cyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice AT lubellwilliamd cyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice AT onghuy cyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice AT marleausylvie cyclicazapeptideligandofthescavengerreceptorcd36srb2reducestheatheroscleroticlesionprogressionandenhancesplaquestabilityinapolipoproteinedeficientmice |